Orano Med

decorative

About Orano Med

Orano Med is an Orano subsidiary created in 2009 to develop innovative therapies to fight cancer.

decorative

Nuclear Medicine

Learn more about nuclear medicine and targeted alpha therapy (TAT) with lead-212, and about our ongoing research.

decorative

Pipeline

Orano Med is always looking for new opportunities to further expand its pipeline.

decorative

News & Materials

Read about the latest news and events, watch a video, or download our brochure.

decorative

Macrocyclics

Macrocyclics, an Orano Med company, is the global leader in chelating agent technologies for medicine.

Latest News

Orano Med extends its production capacity in France and the USA

04/04/2019

Orano Med extends its production capacity in France and the USA

Read more
RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers

01/21/2019

RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers

Read more
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

11/13/2018

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

Read more
Orano Med Video

Click here to view the latest Orano Med Video

Contact

For more information about Orano Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673

Contact

For more information about Macrocyclics, please contact:

Garry Kiefer

Tel.: + 1 (469) 786-6060

CEO Cancer Gold Standard
decorative

Orano Med receives CEO Cancer Gold Standard accreditation

Twitter
decorative

Follow @OranoMed on

Linked In
decorative

Follow Orano Med on